141 related articles for article (PubMed ID: 22348407)
21. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.
Morfini M; Auerswald G; Kobelt RA; Rivolta GF; Rodriguez-Martorell J; Scaraggi FA; Altisent C; Blatny J; Borel-Derlon A; Rossi V
Haemophilia; 2007 Sep; 13(5):502-7. PubMed ID: 17880436
[TBL] [Abstract][Full Text] [Related]
22. Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?
Hedner U
Haemophilia; 2008 Nov; 14 Suppl 6():23-7. PubMed ID: 19134030
[TBL] [Abstract][Full Text] [Related]
23. PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors.
Young G; Auerswald G; Jimenez-Yuste V; Lambert T; Morfini M; Santagostino E; Blanchette V
Thromb Res; 2012 Dec; 130(6):864-70. PubMed ID: 22964026
[TBL] [Abstract][Full Text] [Related]
24. Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) Registry (2004-2008).
Neufeld EJ; Saxena K; Kessler CM; Cooper DL;
Pediatr Blood Cancer; 2013 Jul; 60(7):1178-83. PubMed ID: 23335449
[TBL] [Abstract][Full Text] [Related]
25. Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries.
Bensadok M; Almomen A; Alzoebie A; Benchikh El Fegoun S; Wali Y; Hamzy F; Mehalhal NG; Grifi F; Hamdi S; Mesli N; Owaidah T; Saad HA; Mansour NS; Touhami H
Blood Coagul Fibrinolysis; 2017 Mar; 28(2):145-151. PubMed ID: 27100303
[TBL] [Abstract][Full Text] [Related]
26. Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.
Šalek SZ; Auerswald G; Benson G; Dolan G; Duffy A; Hermans C; Jiménez-Yuste V; Ljung R; Morfini M; Santagostino E; Lambert T
Blood Transfus; 2017 Jan; 15(1):77-84. PubMed ID: 26674816
[TBL] [Abstract][Full Text] [Related]
27. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic.
Salaj P; Brabec P; Penka M; Pohlreichova V; Smejkal P; Cetkovsky P; Dusek L; Hedner U
Haemophilia; 2009 May; 15(3):752-9. PubMed ID: 19432926
[TBL] [Abstract][Full Text] [Related]
28. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group.
Lusher JM; Roberts HR; Davignon G; Joist JH; Smith H; Shapiro A; Laurian Y; Kasper CK; Mannucci PM
Haemophilia; 1998 Nov; 4(6):790-8. PubMed ID: 10028299
[TBL] [Abstract][Full Text] [Related]
29. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.
Hay JW; Zhou ZY
Haemophilia; 2011 Sep; 17(5):e969-74. PubMed ID: 21649802
[TBL] [Abstract][Full Text] [Related]
30. NovoSeven (recombinant factor VIIa) in centeral nervous systems bleeds.
Rice KM; Savidge GF
Haemostasis; 1996; 26 Suppl 1():131-4. PubMed ID: 8904187
[TBL] [Abstract][Full Text] [Related]
31. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
Young G; Shafer FE; Rojas P; Seremetis S
Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
[TBL] [Abstract][Full Text] [Related]
32. Approaches towards successful home treatment in patients with inhibitors.
Ingerslev J; Thykjaer H; Scheibel E
Eur J Haematol Suppl; 1998; 63():11-4. PubMed ID: 9882926
[TBL] [Abstract][Full Text] [Related]
33. Patient-reported experience of bleeding events in haemophilia.
Flood E; Pocoski J; Michaels LA; McCoy A; Beusterien K; Sasanè R
Eur J Haematol; 2014 Jun; 93 Suppl 75():19-28. PubMed ID: 24966142
[TBL] [Abstract][Full Text] [Related]
34. Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia.
Tiede A; Worster A
Ann Hematol; 2018 Oct; 97(10):1889-1901. PubMed ID: 29804265
[TBL] [Abstract][Full Text] [Related]
35. Single higher dose of recombinant activated factor VII in the treatment of hemorrhages in patients with hemophilia complicated by inhibitors.
Łaguna P; Mital A
Adv Clin Exp Med; 2012; 21(4):519-24. PubMed ID: 23240458
[TBL] [Abstract][Full Text] [Related]
36. Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors.
Hay JW; Chaugule SC; Young G
Haemophilia; 2013 Sep; 19(5):711-9. PubMed ID: 23672765
[TBL] [Abstract][Full Text] [Related]
37. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition.
Berntorp E; Collins P; D'Oiron R; Ewing N; Gringeri A; Négrier C; Young G
Haemophilia; 2011 Jan; 17(1):e202-10. PubMed ID: 20825500
[TBL] [Abstract][Full Text] [Related]
38. Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors.
Shapiro AD
Clin Adv Hematol Oncol; 2008 Aug; 6(8):579-86. PubMed ID: 18820600
[TBL] [Abstract][Full Text] [Related]
39. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial.
Kavakli K; Makris M; Zulfikar B; Erhardtsen E; Abrams ZS; Kenet G;
Thromb Haemost; 2006 Apr; 95(4):600-5. PubMed ID: 16601828
[TBL] [Abstract][Full Text] [Related]
40. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
